156 related articles for article (PubMed ID: 32525717)
1. RANK and RANKL Expression in Salivary Gland Tumors.
Aslan F; Küçük Ü
Ear Nose Throat J; 2020 Aug; 99(7):475-480. PubMed ID: 32525717
[TBL] [Abstract][Full Text] [Related]
2. Chemokine and chemokine receptor patterns in patients with benign and malignant salivary gland tumors: a distinct role for CCR7.
Haghshenas MR; Ashraf MJ; Khademi B; Ghaderi A; Erfani N; Razmkhah M
Eur Cytokine Netw; 2017 Mar; 28(1):27-35. PubMed ID: 28840842
[TBL] [Abstract][Full Text] [Related]
3. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
4. RANK and RANK Ligand Expression in Parotid Gland Carcinomas.
Franchi A; Taverna C; Simoni A; Pepi M; Mannelli G; Fasolati M; Gallo O
Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):478-482. PubMed ID: 29494398
[TBL] [Abstract][Full Text] [Related]
5. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.
Szwarc MM; Kommagani R; Jacob AP; Dougall WC; Ittmann MM; Lydon JP
PLoS One; 2015; 10(6):e0128467. PubMed ID: 26061636
[TBL] [Abstract][Full Text] [Related]
7. Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland.
Hai L; Szwarc MM; Lonard DM; Rajapakshe K; Perera D; Coarfa C; Ittmann M; Fernandez-Valdivia R; Lydon JP
Cytokine; 2019 Nov; 123():154745. PubMed ID: 31226438
[TBL] [Abstract][Full Text] [Related]
8. Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.
Steven A; Leisz S; Fussek S; Nowroozizadeh B; Huang J; Branstetter D; Dougall WC; Burchardt M; Belldegrun AS; Seliger B; Pantuck A; Kroeger N
Urol Oncol; 2018 Nov; 36(11):502.e15-502.e24. PubMed ID: 30170981
[TBL] [Abstract][Full Text] [Related]
9. CXCL12 G801A polymorphism is associated with an increased risk of benign salivary gland tumors in the Chinese population.
Liu W; Zhu E; Wang R; Wang L; Liu T
Med Oncol; 2012 Jun; 29(2):677-81. PubMed ID: 21298365
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumors.
Nikitakis NG; Scheper MA; Papanikolaou VS; Sklavounou A; Sauk JJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun; 107(6):837-43. PubMed ID: 19272817
[TBL] [Abstract][Full Text] [Related]
11. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
12. OPG, RANK and RANK ligand expression in thyroid lesions.
Heymann MF; Riet A; Le Goff B; Battaglia S; Paineau J; Heymann D
Regul Pept; 2008 Jun; 148(1-3):46-53. PubMed ID: 18367263
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of oestrogen receptor-α and progesterone receptor in salivary gland tumours.
Kolude B; Adisa A; Adeyemi B; Lawal A
J Oral Pathol Med; 2013 Oct; 42(9):716-9. PubMed ID: 23601083
[TBL] [Abstract][Full Text] [Related]
14. Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Oike N; Sasaki T; Hatano H; Ohashi R; Umezu H; Ajioka Y; Endo N
Tohoku J Exp Med; 2019 Jun; 248(2):87-97. PubMed ID: 31189751
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of the mTOR pathway in intra-oral minor salivary gland neoplasms.
Diamanti S; Nikitakis N; Rassidakis G; Doulis I; Sklavounou A
Oral Dis; 2016 Oct; 22(7):620-9. PubMed ID: 27177463
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease.
Sood SK; Balasubramanian S; Higham S; Fernando M; Harrison B
World J Surg; 2011 Sep; 35(9):1984-92. PubMed ID: 21748518
[TBL] [Abstract][Full Text] [Related]
17. An organoid library of salivary gland tumors reveals subtype-specific characteristics and biomarkers.
Wang B; Gan J; Liu Z; Hui Z; Wei J; Gu X; Mu Y; Zang G
J Exp Clin Cancer Res; 2022 Dec; 41(1):350. PubMed ID: 36527158
[TBL] [Abstract][Full Text] [Related]
18. Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors.
Durr ML; Mydlarz WK; Shao C; Zahurak ML; Chuang AY; Hoque MO; Westra WH; Liegeois NJ; Califano JA; Sidransky D; Ha PK
PLoS One; 2010 May; 5(5):e10828. PubMed ID: 20520817
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of periostin, sclerostin, receptor activator of nuclear factor-κB, and receptor activator of nuclear factor-κB ligand genes in severe chronic periodontitis.
Sankardas PA; Lavu V; Lakakula BVKS; Rao SR
J Investig Clin Dent; 2019 Feb; 10(1):e12369. PubMed ID: 30375186
[TBL] [Abstract][Full Text] [Related]
20. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
